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Background 
Transfusion of blood components is widely utilized in the management of 
medical and surgical conditions.  With the discovery of blood types and advancements 
in medicine, transfusion can be a life-saving intervention.  One of the most important 
reasons for red blood cell (RBC) transfusion is to restore, or maintain, oxygen delivery to 
vital organs in the human body.  Fresh frozen plasma (FFP) transfusion is utilized to treat 
coagulopathies, life threatening bleeding diathesis and reverse effects of warfarin.  
Cryoprecipitate is indicated for the treatment of von Willebrand’s disease, Hemophilia 
A, Factor XIII deficiency and hypofibrinogenemia, especially when recombinant products 
are not available.  In 2003, the National Blood Data Resource Center estimated that 14 
million units of whole blood were collected, processed into 27 million units of blood 
products and subsequently transfused in to 4.5 million medical and surgical patients in 
the United States.1  Though transfusion is a life-saving intervention, there is continuing 
debate about the standardization of blood transfusion practices.  Not only has blood 
become a scarce resource in a large growing population, but transfusion of blood and 
blood products also carry significant risks.   
 Oxygen is carried in red blood cells and reversibly bound to the tetramer 
hemoglobin.  Adequate oxygenation of the tissues is dependent on the balance of 
oxygen consumption and oxygen delivery.  Oxygen consumption can remain constant 
over a wide range of oxygen delivery.  However as oxygen delivery reaches a critical 
threshold, tissue extraction of oxygen cannot be further increased to meet the 
metabolic needs of the tissue.  Oxygen delivery below the critical threshold results in 
P a g e  | 2 
 
 
 
the beginning of anaerobic metabolism and the production of substrates such as lactate, 
nicotinamide adenine dinucleotide (NADH), and reduced cytochrome oxidase.  This 
critical threshold of oxygen delivery occurs at different levels in different organ systems.  
The critical threshold is dependent on the regional and global blood flow regulation, as 
well as the metabolic needs of the organs.   
 Oxygen delivery (DO2) to the whole body is dependent on the relationship 
between cardiac output (CO) and oxygen content (CaO2) in the arterial blood [equation 
1].  Oxygen consumption (VO2) in the whole body is dependent on cardiac output and 
the oxygen content difference between arterial (CaO2) and venous blood (CvO2) 
[equation 2]. 
DO2 = CO × CaO2 (normal range: 460 to 650 mL/min/m
2)  
[equation 1] 
 
VO2= CO × (CaO2– CvO2) (normal range: 96 to 170 mL/min/m
2) 
[equation 2] 
 
Where: 
CaO2 = (Hb × 1.39 × SaO2) + (0.003 × PaO2)  
CvO2 = (Hb × 1.39 × SvO2) + (0.003 × PvO2)  
 
Hb, hemoglobin; SaO2, arterial oxygen saturation; PaO2, arterial oxygen 
tension; SvO2 mixed venous oxygen saturation; PvO2, mixed-venous oxygen 
tension  
 
Reduction in whole body oxygen delivery can therefore result from either, 
decrease in cardiac output, or decrease in arterial blood oxygen content (profound 
anemia, massive hemorrhage, hypoxemia, and decrease in oxygen saturation).  In 
addition to cardiac output and arterial blood oxygen content influencing whole body 
oxygen delivery, microvascular capillary regulatory mechanisms can also affect tissue 
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oxygen delivery.  Functional physiologic shunting can decrease tissue oxygen delivery, 
while pharmacologic manipulation of microvasculature can increase tissue oxygen 
delivery.2 
 Theoretically, red blood cell transfusion is capable of enhancing arterial blood 
oxygen content, and thereby increasing total whole body oxygen delivery.  However the 
use of red blood cell transfusion to manipulate and potentially increase tissue oxygen 
delivery is complex and its efficacy is not completely clear.3-7  Transfusion increases 
hemoglobin levels (hence increase in oxygen content) and in cases where there is a 
reduction of preload, transfusion can additionally increase cardiac output and thus total 
body oxygen delivery.  However, increasing hemoglobin levels and oxygen content via 
transfusion may not lead to the immediate desired result of increase oxygen delivery at 
the tissue level.8-12 The transfusion of stored red blood cells can trigger biochemical and 
inflammatory reactions and potentially result in decreased oxygen delivery at the tissue 
level.8-12  
 Fresh frozen plasma is one of the least understood blood products. It contains 
albumin, globulins, fibrinogen and other coagulation factors. Even though it has limited 
recommendations for its use, it is most often used to treat bleeding disorders when a 
coagulation factor or multiple coagulation factors are deficient or no coagulation factor-
specific concentrate is available.13  Recommended uses for fresh frozen plasma are 
listed in table 1.  Fresh frozen plasma is the most frequently misused blood product.14,15 
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Table 1. Recommended uses for FFP 
Single coagulation factor deficiencies 
Multiple coagulation factor deficiencies with severe bleeding in disseminated 
intravascular coagulation (DIC) 
Thrombotic thrombocytopenic purpura (TTP) 
Reversal of warfarin effect 
Surgical bleeding and hemostasis 
Hemorrhagic disease of the newborn 
Neonates with coagulopathy and in need for a surgical procedure 
Red cell T antigen in newborns 
 
 Cryoprecipitate is the portion of the plasma that is rich in coagulation factors, 
including factor VIII, fibrinogen, von Willebrand factor and factor XIII.13  Cryoprecipiate is 
used primarily for the reversal of hypofibrinogenemia caused by massive transfusion or 
disseminated intravascular coagulation (DIC).  It is also considered for use in treatment 
of von Willenbrand’s disease, Hemophila A, and Factor XIII deficiency when recombinant 
products are not available.   
Platelets are administered to treat either thrombocytopenia or provide 
functional platelets. Thrombocytopenia, a decrease in number of circulating platelets, is 
caused by either an increased destruction (idiopathic, immunologically-mediated, DIC) 
or decreased production of platelets (myelosuppressive drugs, radiation, chronic alcohol 
use). 
Blood component therapy can be potentially life-saving and at the same time 
can have deleterious effects.  Thus transfusion of blood products should not be taken 
lightly.  Ideally blood product should only be transfused when necessary. If clinicians 
could easily monitor for optimal oxygen delivery and coagulation status, blood product 
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transfusions could be optimized.  However, in rapidly changing clinical situations, it is 
challenging to predict the need for blood products precisely. With this in mind, 
transfusion triggers or thresholds based on measurable physiological parameters, could 
aid and guide clinicians in making the decision for transfusion therapy.  It is expected 
that these transfusion thresholds are developed from quality evidence and based on 
rigorous clinical trials and studies that demonstrate improvement in patient outcomes.   
 
History of Perioperative Transfusion 
There is significant variability in transfusion practices among the different 
medical specialties.  Historically, a hemoglobin of 10 g/dL and a hemotocrit of 30% were 
widely used and accepted as “transfusion triggers” for red blood cell transfusion 
particularly in the surgical setting.16  In the 1970s, red blood cells were often times 
withheld until symptoms of anemia developed or there was a clinically significant drop 
of <10 g/dL in hemoglobin.17-19  In 1988 the National Heart, Lung and Blood institute, the 
Office of Medical Applications of Research, the Warren Grant Magnuson Clinical Center 
of the National Institute of Health, and the Food and Drug Administration convened the 
Consensus Development Conference on Perioperative Red Cell Transfusion to discuss 
the criteria for perioperative red blood cell transfusion, the morbidity of anemia in the 
perioperative period, and immediate and long-term risks of transfusion.  This consensus 
conference concluded that available evidence at the time did not support a single 
criterion for red blood cell transfusion, mild-moderate anemia did not contribute to 
perioperative morbidity, and transfusions should be kept to a minimum due to the 
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documented risks of infection and deleterious immune modulation.20  The consensus 
conference concluded that future research was necessary to define the best indications 
for perioperative red blood cell transfusion.   
Different authors have suggested a range of hemoglobin levels as criterion for 
transfusion (6.0-10.0g/dL), depending on the presence of several co-morbidities.21-23  In 
1999, the Canadian Critical Care Trials Group demonstrated that a restrictive strategy of 
red blood cell transfusion in 838 critically ill patients reduced hospitalization mortality 
rates in a multicenter, randomized controlled clinical trial referred to as the Transfusion 
Requirements in Critical Care (TRICC) trial.24 Except in patients with acute myocardial 
infarction and unstable angina, a restrictive transfusion strategy (threshold of 
hemoglobin 7.0g/dL; hemoglobin range of 7.0-9.0g/dL) was as effective, if not 
significantly better at lowering hospital mortality rates, than a liberal transfusion 
strategy (hemoglobin threshold of 10.0g/dL; hemoglobin range of 10.0-12.0g/dL).    
In 2001, a randomized controlled clinical trial was performed to determine if a 
low transfusion threshold was safe in critically ill patients with known cardiovascular 
disease.25  This study concluded that there was no difference in mortality or myocardial 
infarction rates in the restrictive (transfusion threshold of hemoglobin 7.0g/dL; 
hemoglobin range 7.0 - 9.0g/dL) versus liberal (transfusion threshold of hemoglobin 
10.0g/dL; hemoglobin range 10.0 - 12.0g/dL) transfusion groups.25 However, it 
suggested that a restrictive transfusion strategy appeared to be safe in most patients 
with cardiovascular disease, with the exception of patients with acute myocardial 
infarcts and unstable angina.  On the contrary, in other studies, in patients undergoing 
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coronary artery bypass graft surgery or myocardial revascularization there was no 
difference in mortality rates when a restrictive (hemoglobin 8.0g/dL) transfusion 
threshold was compared to a liberal (9.0g/dL) transfusion threshold.26,27 
In contrast to packed red blood cells, there is little data on the relationship of 
transfusion of coagulation blood products, such as platelets, fresh frozen plasma, 
cryoprecipitate, and patient outcomes.  Of the coagulation blood products mentioned, 
there are more data about the transfusion of platelets in the perioperative period.  In 
2004, a study with 1,720 patients who received platelet transfusion, suggested a 
significant association between platelet transfusion and the risk of infection, stroke and 
death.28   There have been no prospective randomized trials to date investigating the 
liberal or prophylactic use of platelet transfusion and its association with increased rate 
of stroke and death.  Moreover, there is limited data from randomized controlled trials 
regarding the threshold for transfusion of fresh frozen plasma and cryoprecipitate, and 
patient outcomes. 
 
Risks of Blood Product Transfusion 
More than twenty years ago, blood and blood component transfusion were 
thought to be relatively safe.  Then in the 1980s, up to 1 in 100 blood units in the United 
States was found to transmit the human immunodeficiency virus (HIV) or hepatitis C 
virus (HCV), as plasma did not undergo viral inactivation.29  There have been significant 
advancements in transfusion medicine in the past 30 years, such as nucleic-acid testing, 
that have reduced the estimated residual risk of infection with the HIV or HCV to 1 in 1.5 
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million to 1 in 2 million units transfused.30  Current risk of transmission of blood-borne 
viruses are listed in table 2.31 
Table 2.  Contemporary risk of transmitting any of the blood-borne viruses.31 
Virus Risk per Unit 
Transfusion 
Transmission 
Rate 
Window 
Period 
Human Immunodeficiency 
Virus 1&2 
1:2,135,000 90% 11 days 
Hepatitis C Virus 1:1,935,000 90% 10 days 
Hepatitis B Virus 1:205,000 70% 59 days 
Human T-lymphotrophic 
Virus 
1:3,000,000 30% 51 days 
West Nile Virus 1:10,000 to 1,000* unknown - 
Parvovirus B19 1:40,000 to 3,000 low - 
Hepatitis A/E 1:1,000,000 low - 
*prior to nucleic acid testing 
 
Emerging infections, defined as those infections whose incidence in humans has 
increased within the past two decades or threatens to increase in the near future, may 
have an asymptomatic blood-borne phase and may exist and can be transmittable by 
transfusion.  Current infectious agents that are emerging to threaten blood and blood 
component safety include, but are not limited to, are: human variant Creuztfeld-Jakob 
disease, West Nile virus, Babesia species, GB virus C-hepatitis G virus, SEN virus, TT 
virus, human herpesvirus 8, and simian foamy virus.32-34   
Though transmission of infection by blood transfusion has decreased 
significantly, transfusion-related acute lung injury (TRALI) has now become the leading 
cause of transfusion related mortality.  Fresh frozen plasma administration has been 
shown to be an independent risk factor for TRALI in trauma, medical and surgical ICU 
patient populations in the United States.35  Intensive care unit patients, enrolled in the 
2004 CRIT (Anemia and Blood Transfusion in CRITical Care) study, who received red 
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blood cell transfusions experienced a higher incidence of overall complications.  The 
study demonstrated that the number of red blood cell transfusions a patient received 
was independently associated with a longer ICU stay, length of hospital stay, and 
increase in mortality.36  With these current transfusion risks in mind, practitioners are 
relying heavily on transfusion practice guidelines and recommendations.  The goal of 
these clinical transfusion practice guidelines and recommendations is to limit 
unnecessary transfusion of blood products, improve blood component transfusion 
therapy for patients and hopefully improve clinical outcomes.  
 
History of the Development of Transfusion Guidelines 
The development of guidelines were proposed in 1990 by the Institute of 
Medicine to reduce inappropriate health care variation by aiding physician decision-
making.37  Decision-making in healthcare should acknowledge benefits and risks of 
medical interventions, as well as the underlying quality of evidence to support such 
interventions.    
The number of practice guidelines has mushroomed significantly, with each of 
the medical societies developing their own set of guidelines for areas of interest for 
them. 38 A variety of medical specialties have published recommendations, on the use of 
blood products, to guide clinicians in their transfusion decisions.  In the 1980s, the 
National Institute of Medicine held consensus conferences on the use of red blood cells, 
fresh frozen plasma, and platelets.39-41  In the 1990s, the American College of Physicians 
and American College of Pathologists issued guidelines regarding red blood cell and 
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fresh frozen plasma, cryoprecipitate and platelet transfusion respectively.42,43  The 
American Association of Blood Banks also generated guidelines regarding transfusion 
during coronary artery bypass graft surgery and appropriate blood utilization.44,45  In the 
same decade, the American Society of Anesthesiologists (ASA) developed a Task Force 
to develop guidelines regarding blood component therapy.46  However, the 
consequence of numerous guidelines from multiple specialties results in varying 
recommendations for each intervention, which can be confusing for physicians. 
Furthermore, when several physicians are involved in the care of a patient, their 
decisions when to transfuse can differ significantly, based on what guideline the care-
giver is following. 
Guidelines for physicians should comprise of the following: the scope of the 
practice guidelines, current interventions and practices considered, strength of 
recommendations and the quality of used evidence.  The recommendations developed 
in guidelines ideally should be based on strong evidence.  However in actuality, 
guidelines may generate strong recommendations on consensus expert opinions rather 
than on high quality evidence.37  In addition, these guidelines use multiple systems to 
grade the quality of evidence, as well as to classify the strength of their 
recommendations. Thus, it is important to compare and analyze current guidelines, to 
determine variations in recommendations and if the recommendations generated to 
guide clinicians are truly supported by quality evidence.  In addition, it is also important 
to consider and evaluate guidelines for the composition of their working group, types of 
studies used to develop guidelines, and the specific methodologies utilized to grade 
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evidence and classify recommendations. In this thesis, we compared different guidelines 
for variations in guideline development, recommendations and their level of evidence.  
 
Methods  
A comprehensive literature search on clinical transfusion guidelines of blood 
components was identified and performed using the following computer databases: 
PubMed/Medline, Cochrane Central, Scopus and the National Guideline Clearinghouse.  
Additional websites and publications of relevant scientific societies, such as the 
Australian and New Zealand Society of Blood Transfusion, were also searched for 
guidelines missed from the computer database search.  Key words that were used for 
searching the databases include the combination of the following keywords: blood, 
blood component, blood product, transfusion, guidelines.  Of those database searches 
of articles, only articles from January 2005 to October 2010 written in the English 
language were retrieved. The articles/guidelines were limited to the last 5 years as we 
assumed that the literature within that time frame was most current and clinically 
relevant.  However some guidelines outside of this time period were included, in order 
to provide complete representation of guideline recommendations from countries not 
represented in the initial computer database searches.  In these cases, only the most 
current practice guideline published from the societies were utilized.  Relevance of the 
articles to be retrieved was evaluated and included if there were clear transfusion 
indications and recommendations stated within the article.  Articles regarding 
transfusion practices in children or neonates were not included in this study.  A total of 
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eleven international guidelines were included in this study for final analysis ranging from 
the year 2001 to 2010.   
The resulting eleven guidelines were analyzed for the following areas:  
characteristics and composition of the guideline working group panel, literature and 
evidence utilized for the systematic review, databases utilized to retrieve evidence and 
literature for the systematic review, methodologies employed by guideline committees 
to grade strength and quality of evidence and recommendations, quantity of 
recommendations suggested, and specific transfusion thresholds and/or clinical settings 
for transfusion of blood products. 
The eleven guidelines use seven different systems to grade the strength of 
recommendations and the level of evidence.  In order to help us compare the level of 
evidence and strength of recommendations amongst these guidelines, we developed a 
three-tiered classification system for both grading level of evidence and strength of 
recommendation (Table 2 and 3).  This system was applied to all eleven guidelines 
reviewed. The terms “strong,” “intermediate,” and “low” level of evidence as used in 
this thesis are described and defined in table 3.  The terms “strong,” “intermediate,” 
and “low” grade of recommendation as used in this thesis are described and defined 
table 4. 
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Table 3. Compilation of Level of Evidence Grading 
Grading of 
Evidence 
GRADE AHRQ USPSTF  
(After 
May 
2007) 
USPSTF    
(Before 
May 
2007) 
AHA/ACC NHMRC ASA 
STRONG High/A 1A High 
(Class I) 
Good A I Support 
  1B    II  
INTERMEDIATE Moderate/B 2A Moderate 
(Class II) 
Fair B III1 Suggest 
  2B    III2  
LOW Low /C 3 Low  
(Class III) 
Poor C III3 Equivocal 
 Very Low /D 4    IV Silent 
       Insufficient 
       Inadequate 
GRADE = Grading of Recommendations, Assessment, Development, and Evaluation 
USPSTF = U.S. Preventative Task Force 
ACC/AHA = American College of Cardiology/American Heart Association 
ASA = American Society of Anesthesiologists 
NHMRC = Australian National Health and Medical Research Council 
ARHQ = Agency for Healthcare Research and Quality 
 
 
Table 4. Compilation Strength of Recommendation Classification 
Strength of 
Recommendation 
GRADE AHRQ USPSTF  
(After 
May 
2007) 
USPSTF    
(Before 
May 
2007) 
AHA/ACC NHMRC ASA 
STRONG Strong 
(1) 
 A (Level 
1) 
A Class I A Strongly 
agree 
    B   Agree 
INTERMEDIATE   B (Level 
2) 
C Class IIa B Equivocal 
   C  Class IIb   
WEAK Weak 
(2) 
 D (Level 
3) 
D Class III C Disagree 
   I I  D Strongly 
disagree 
GRADE = Grading of Recommendations, Assessment, Development, and Evaluation 
USPSTF = U.S. Preventative Task Force 
ACC/AHA = American College of Cardiology/American Heart Association 
ASA = American Society of Anesthesiologists 
NHMRC = Australian National Health and Medical Research Council 
ARHQ = Agency for Healthcare Research and Quality 
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Results 
The bibliographic search conducted was limited to articles written in the English 
language published during the period from January 2005 to October 2010.  A 
comprehensive literature search to identify guidelines relevant to transfusion of blood 
components was performed and yielded the following results: PubMed/Medline (701), 
Cochrane Central (38), Scopus (4,292), and the National Guidelines Clearinghouse 
(2,073).  Additional publications from relevant scientific societies, such as the Australian 
and New Zealand Society of Blood Transfusion, were also searched to identify guidelines 
missed from the database screen.  An initial screening of these references identified 
potentially relevant articles.  The final analysis of these articles resulted in the 
identification of 11 international guidelines addressing clinical transfusion practices of 
blood components.   
 
Guidelines Working Group Panel Composition 
Table 5 and figure 1 report the panel composition of working groups for each of 
the eleven guidelines.  To address the composition of working groups that prepared 
guidelines we looked at the number of total members, medical specialties represented, 
international/national societies represented, and consulting methodologists involved in 
the working group panels.  Six of eleven guidelines reported the number of medical 
specialties represented by each panel member. However, only five guidelines detailed 
the number of international/national medical societies represented by each panel 
member. Similarly, five of eleven guidelines reported the total number of members 
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composed their working group. Only two of eleven guidelines reported involving 
consultant methodologists in the working group panel.   
 
Table 5.  Working Group Panel Composition 
Author Number of 
members 
Number of 
specialties 
represented 
Number of 
societies 
represented 
Number of 
consulting 
methodologists 
Roback et al (2010) 17 6 (9 members) 6 3 
Napolitano et al 
(2009) 
NM 5 2 NM 
Dellinger et al (2008) 55 NM 16 NM 
Ferraris et al (2007) 17 NM NM NM 
Spahn et al (2007) NM 5 5 NM 
Stainsby et al (2006) 100 NM 3 NM 
Wong et al (2007) NM 2 NM NM 
Droubatchevskaia et 
al (2007) 
NM 3 NM NM 
ASA Task Force 
(2006) 
10 4 NM 2 
New Zealand (2001) NM 3 NM NM 
Cochrane (2009) NM NM NM NM 
(“NM “ indicates not mentioned) 
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Figure 1. Number of Members in Working Group Panel 
 
 
 
Table 6 and figure 2 report the number of medical specialties represented in 
each working group panel for the eleven guidelines.  Six of the eleven guidelines 
reported having a panel member specialized in internal medicine and/or critical care 
medicine. Five of the eleven guidelines reported having a panel member specialized in 
hematology, anesthesiology, or surgery.  Within the guidelines mentioning a panel 
member specializing in surgery, three specified having a member from trauma and/or 
thoracic surgery. Three of the eleven guidelines also reported having a panel member 
specialized in pathology. Pediatrics, obstetrics, transfusion pathology, oncology, 
transfusion medicine were mentioned to be represented in only one of the guidelines.   
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One of eleven guidelines reported five medical specialties represented, three of eleven 
guidelines reported four medical specialties represented, one of eleven guidelines 
reported three medical specialties represented, two of eleven guidelines reported two 
medical specialties represented, and two of eleven guidelines reported only one medical 
specialty represented in the working group panel.  Emergency medicine, pediatrics and 
obstetrics specialties were reported in the working group panel of only one guideline.  
Orthopedic surgery, vascular surgery, oncologic surgery, solid organ transplant surgery 
and neurosurgery were not represented (or mentioned) in any of the eleven guidelines. 
Table 6.  Medical Specialties Represented in Working Group Panel 
Author Hematology Pathology Anesthesiology Internal 
Medicine/Cri
tical Care 
Emergency 
Medicine 
Pediatrics Surgery 
(Thoracic/ 
Trauma) 
Obstetrics Total 
Number of 
Specialties 
Roback et al 
(2010) 
X (9) X (9) X(2) X (4) NM X(2) NM NM 5 
Napolitano 
et al (2009) 
NM NM NM X (?) NM NM X (?/Trauma) NM 2 
Dellinger et 
al (2008) 
NM NM NM X (?) NM NM NM NM 1 
Ferraris et 
al (2007) 
NM NM X NM NM NM X (Thoracic) NM 2 
Spahn et al 
(2007) 
X NM NM X X NM X (?/Trauma) NM 4 
Stainsby et 
al (2006) 
X NM NM NM NM NM NM NM 1 
Wong et al 
(2007) 
X X X X 
(Transfusion) 
NM NM NM NM 3 
Droubhatch
evskaia et 
al (2007) 
X X NM X NM NM NM NM 3 
ASA Task 
Force 
(2006) 
NM X 
(Transfusion) 
X NM NM NM X X 4 
New 
Zealand 
(2001) 
X NM X X (Oncology) NM NM X NM 4 
Cochrane 
(2009) 
NM NM NM NM NM NM NM NM NM 
(“NM “ indicates not mentioned) 
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Figure 2.  Number of Medical and Surgical Specialties Represented 
 
 
 
Evidence and Systematic Reviews Utilized to Generate Guidelines 
Table 7 demonstrates the study design of the evidence utilized in the 
development of the eleven guidelines.  Four of the eleven guidelines reviewed listed 
detailed methods of their literature review and their study design of the literature 
searched and reviewed.  One guideline only mentioned the study designs they excluded 
from their literature search.  Five of eleven guidelines analyzed in this study did not 
reveal the study designs of the literature they utilized in their search and in the 
development of their guidelines. 
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Table 7.  Systematic review:  Study Design of Evidence Utilized 
Author Randomized 
Controlled 
Trials 
Case 
Control 
Case 
Reports 
Observational Systematic 
Reviews 
Meta-
analysis 
Guidelines Abstracts Editorials 
Roback et al (2010) X   X      
Napolitano et al 
(2010) 
  excluded  excluded    Excluded 
Dellinger et al 
(2008) 
NM 
Ferraris et al (2007) X  X X      
Spahn et al (2007) X X X X X  X X  
Stainsby et al 
(2006) 
NM 
Wong et al  (2007) NM 
Droubatchevskaia 
et al (2007) 
NM 
ASA Task Force 
(2006) 
NM 
New Zealand 
(2001) 
    X X    
Cochrane (2009) NM 
(“NM “ indicates not mentioned) 
 
Table 8 demonstrates the databases utilized to yield the literature searches and 
reviews performed by each working group for the eleven international guidelines.  Six of 
the eleven guidelines utilized Pubmed/Medline searches and four of the eleven 
guidelines utilized Cochrane Central searches.  One guideline utilized EMBASE, one 
guideline utilized National Library of Medicine, and another guideline utilized Current 
Contents.  Four of the eleven guidelines did not reveal the types of databases utilized 
when performing their literature searches for their guideline development. 
Table 8.  Systematic review:  Databases Utilized 
Author Medline/PubMed EMBASE Cochrane 
Central 
National 
Library of 
Medicine 
Current 
Contents 
Roback et al (2010) NM 
Napolitano et al (2010) X X X X  
Dellinger et al (2008) X     
Ferraris et al (2007) NM 
Spahn et al (2007) X  X   
Stainsby et al (2006) X  X   
Wong et al (2007) X     
Droubatchevskaia et al 
(2007) 
     
ASA Task Force (2006) NM 
New Zealand (2001) NM 
Cochrane (2009) X  X  X 
(“NM “ indicates not mentioned) 
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Methodology Utilized to Grade Evidence 
Table 9 reports the methodology utilized by the eleven guideline’s working 
groups to grade and rate evidence.  Three of the eleven guidelines either utilized the 
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) 
methodology, or the Agency for Healthcare Research and Quality (AHRQ) 
methodology.47-51  The five guidelines not utilizing the GRADE or AHRQ methodologies, 
utilized any one of the following: the U.S. Preventative Task Force (USPSTF) 
methodology, American College of Cardiology/American Heart Association (ACC/AHA) 
methodology, Australian National Health and Medical Research Council (NHMRC) 
methodology or the American Society of Anesthesiologists (ASA) methodology.52-55 
Table 9.  Methodology utilized by Guideline Committees to Rate Evidence 
Author GRADE USPSTF ACC/AHA ASA NHMRC ARHQ Cochrane 
Roback et al (2010) X       
Napolitano et al (2010)  X      
Dellinger et al (2008) X       
Ferraris et al (2007)   X     
Spahn et al (2007) X       
Stainsby et al (2006)      X  
Wong et al (2007)      X  
Droubatchevskaia et al 
(2007) 
     X  
ASA Task Force (2006)    X    
New Zealand (2001)     X   
Cochrane (2009)       X 
TOTAL 3  1 1  1 1 3  1 
GRADE = Grading of Recommendations, Assessment, Development, and Evaluation 
USPSTF = U.S. Preventative Task Force 
ACC/AHA = American College of Cardiology/American Heart Association 
ASA = American Society of Anesthesiologists 
NHMRC = Australian National Health and Medical Research Council 
ARHQ = Agency for Healthcare Research and Quality 
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Practice Guideline Recommendations 
 Table 10 and figure 3 represent the total number of recommendations made by 
the working group panel regarding use of blood and blood product transfusion in the 
perioperative setting. The total number of recommendations ranged from one to 
twenty-eight total recommendations for each of the guidelines.  A total of 107 
recommendations were generated about packed red blood cells, fresh frozen plasma, 
platelets, and cryoprecipitate transfusion.  Of the 107 recommendations, 48 (48.86%) of 
the recommendations were specific to the use of packed red blood cells, 31 (28.97%) of 
the recommendations were specific to the use of fresh frozen plasma, 15 (12.02%) of 
the recommendations were specific for the use of platelets, and only 13 (12.15%) 
recommendations were specific to the use of cryoprecipitate. (Figure 3)   
Table 10.  Number of Recommendations Suggested for each Component of Blood 
Therapy 
Author Packed Red 
Blood Cells 
Fresh Frozen 
Plasma 
Platelets Cryoprecipitate Total 
Regarding 
Blood 
Products 
Roback et al (2010) 1 6 0 0 7 
Napolitano et al 
(2010) 
 28 0 0 0 28 
Dellinger et al (2008) 2 1 1 0 4 
Ferraris et al (2007) 9 0 0 0 9 
Spahn et al (2007) 1 1 3 1 6 
British Columbia 
(2006/2007) 
1 11 7 2 21 
ASA Task Force (2006) 2 5 3 3 8 
New Zealand (2001) 3 7 6 2 14 
Cochrane (2009) 1 0 0 0 1 
TOTAL 48/107 
(48.86%) 
31/107 
(28.97%) 
15/107 
(12.02%) 
13/107 
(12.15%) 
107/107 
(100%) 
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Figure 3.  Total Number of Recommendations 
 
Of the 107 recommendations, table 11 and figure 4 demonstrate that only 12 
(11.21%) recommendations were generated from “strong” level evidence, 25 (23.36%) 
recommendations were generated from “intermediate” level evidence, and 70 (65.42%) 
recommendations were generated from “low” level evidence.   
 
Table 11. Level of Evidence Utilized for All Blood Product Recommendations 
Level of Evidence Packed Red 
Blood Cells 
Fresh Frozen 
Plasma 
Cryoprecipitate Platelets Number/Total (%) 
STRONG 4 (8.33%) 7 (22.58%) 0 (0.00%) 1 (6.67%) 12/107 (11.21%) 
INTERMEDIATE 24 (50.00%) 1 (3.23%) 0 (0.00%) 0 (0.00%) 25/107 (23.36%) 
LOW 20 (41.67%) 23 (74.19%) 13 (100%) 14 (93.33%) 70/107 (65.42%) 
Total 48 31 13 15 107/107 (100%) 
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Figure 4.  Level of Evidence Utilized for All Blood Product Recommendations 
 
 
Of the 107 recommendations, table 12 and figure 5 demonstrate that 36 
(33.64%) recommendations were classified as a “strong” recommendation to perform 
the intervention, 46 (42.99%) recommendations were classified as an “intermediate” 
recommendation to perform the intervention, and 25 (23.36%) recommendations were 
classified as a “weak” recommendation to perform the intervention. 
 
Table 12. Strength of Recommendations for All Blood Products 
Strength of 
Recommendation 
Packed Red 
Blood Cells 
Fresh 
Frozen 
Plasma 
Cryoprecipitate Platelets Number/Total 
(%) 
STRONG 10 (20.83%) 
9 (29.03%) 7 (53.85%) 10 (66.67%) 36/107 (33.64%) 
INTERMEDIATE 31 (64.58%) 10 (32.26%) 5 (38.46%) 0 (0.00%) 46/107 (42.99%) 
WEAK 7 (14.58%) 12 (38.71%) 1 (7.69%) 5 (33.33%) 25/107 (23.36%) 
Total 48 31 13 15 107/107 (100%) 
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Figure 5. Strength of Recommendations for All Blood Products 
 
 
Recommendations Regarding Clinical Use of Red Blood Cells 
Table 10 demonstrates that a total of 48 of the 107 recommendations were 
relevant to packed red blood cell use.  Of the 48 recommendations, table 11 and figure 
6 demonstrate that 4 (8.33%) recommendations were generated from “strong” level of 
evidence, 24 (50.00%) recommendations were generated by “intermediate” level 
evidence, and 20 (41.67%) recommendations were generated by “low” level evidence.   
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Figure 6.  Level of Evidence Utilized for Packed Red Blood Cell Recommendations 
 
Of the 48 recommendations, table 12 and figure 7 demonstrate that 10 (20.83%) 
recommendations were classified as a “strong” recommendation to perform the 
intervention, 31 (64.58%) recommendations were classified as an “intermediate” 
recommendation to perform the intervention, and 7 (14.58%) recommendations were 
classified as a “weak” recommendation to perform the intervention.  Of the 10 “strong” 
recommendations, 1 (10.00%) recommendation was based on “strong” level of 
evidence, 3 (30.00%) recommendations based on “intermediate” level of evidence, and 
6 (60.00%) recommendations based on “low” level of evidence (Figure 8). 
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Figure 7.  Strength of Recommendations for Packed Red Blood Cells 
 
 
Figure 8. Level of Evidence for “Strong” Recommendations regarding use of RBC 
 
 
Appendix table 1 summarizes the eleven international guideline 
recommendations for the clinical use of packed red blood cells.  Of the guidelines 
reviewed, 7 of 10 international guidelines have commented on the indications and 
utilization of packed red blood cells.  A target Hb level of 7-9g/dL is recommended 
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(Dellinger, Level 1B; Spahn, Grace 1C) 51,56, but other target ranges such as Hb 6-10g/dL 
(ASA, strongly) or 7-10g/dL (Australia, Level IV) has also been recommended as well. 
51,54-56 
Five guidelines stated RBC should be administered when the hemoglobin level is 
<7g/dL (Table 13).  Napolitano et al  recommended consideration of transfusion with a 
Hb <7g/dL in critically ill patients with acute hemorrhage, with hemodynamic instability, 
with inadequate oxygen delivery (Level 1), requiring mechanical ventilation or 
resuscitated critically ill trauma and stable cardiac patients without acute myocardial 
ischemia (Level 2), and Ferraris et al stated it was reasonable for transfusion with a Hb 
<7g/dL in most post-operative patients (Class 2A, C), and not unreasonable for patients 
on cardiopulmonary bypass with risk for critical end-organ ischemia/injury (Class 2B, C). 
52,53  Dellinger et al strongly recommended the threshold for giving RBC be Hb<7g/dL 
with a target hemoglobin of 7-9g/dL in adults.  They also suggested that a higher 
hemoglobin level may be required in the setting of myocardial ischemia, severe 
hypoxemia, acute hemorrhage, cyanotic heart disease, or lactic acidosis in patients 
(Level 1B, Strong). 56 
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Table 13. Guidelines recommending transfusion threshold of Hb <7 g/dL 
Organization Recommendation Evidence 
Napolitano (USPTF) Level 1 (convincingly justifiable 
based on scientific evidence) 
Level 2 (reasonable scientific 
evidence and strong expert opinion) 
Class 1, Class 2 (Prospective 
RCT, strong prospective and 
retrospective analysis) 
Class 2, Class 3 (Strong 
prospective and retrospective 
analysis, retrospective data 
collection) 
Dellinger (GRADE) Strong / Grade 1 (Recommend; 
benefits do or do not outweigh 
harm and burden) 
Class B (Moderate; RCT with 
important limitations or very 
strong evidence from 
observational studies or case 
series) 
Ferraris (ACC/AHA) Class 2B (Usefulness/efficacy is less 
well established by 
evidence/opinion) 
Level C (Consensus opinions of 
experts) 
New Zealand (NHMRC) - Level IV (Evidence obtained 
from case series, either post-
test or pretest and post-test) 
 
In Table 14 Napolitano et al suggested that a transfusion threshold of Hb </= 
8g/dL may be beneficial in patients with acute coronary syndromes who are anemic on 
hospital admissions (Level 3).52  More “restrictive” hemoglobin transfusion triggers were 
recommended by several guidelines.  
Table 14. Guidelines recommending transfusion threshold of Hb </= 8g/dL 
Organization Recommendation Evidence 
Napolitano (USPTF) Level 3 (Supported by data but lacking 
adequate scientific evidence) 
Class 3 (retrospective data 
collection) 
British Columbia (AHCPR) Grade C (Absence of directly 
applicable clinical studies of good 
quality) 
Level IV (Evidence from expert 
committee reports or opinions 
and/or clinical experiences of 
respected authorities) 
 
In Table 15 Ferraris et al stated that for hemoglobin levels <6g/dL, transfusion 
with RBC is reasonable and can be life-saving (Class 2A, C), reasonable and life-saving 
for cardiac operations (Class 2A, C), reasonable during cardiopulmonary bypass with 
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moderate hypothermia except in patients at risk for decreased cerebral oxygen delivery, 
such as those with histories of cardiovascular disease, diabetes mellitus, cerebrovascular 
disease, and carotid stenosis  (Class 2A, C), and additionally the ASA Task Force strongly 
agreed upon in the setting of a young, healthy patient especially when the anemia is 
acute and without low cardiopulmonary reserve and high oxygen consumption 
(strongly). 53,54 
Table 15. Guidelines recommending transfusion threshold of Hb <6 g/dL 
Organization Recommendation Evidence 
Ferraris (ACC/AHA) Class 2A (weight of evidence/opinion is 
in favor of usefulness/efficacy) 
C (consensus opinions of experts) 
British Columbia (AHCPR) Grade C (absence of directly applicable 
clinical studies of good quality) 
Level IV (evidence from expert 
committee reports or opinions 
and/or clinical experiences of 
respected authorities) 
ASA Strongly agree Insufficient 
 
In Table 16 four guidelines did not support the use of 10g/dL as a hemoglobin 
transfusion trigger for RBC.  Napolitano et al stated there is no benefit of a “liberal” 
transfusion when Hb >10g/dL in critically ill patients on mechanical ventilation, 
resuscitated critically ill trauma patients, critically ill patients with stable cardiac disease, 
or in patients with moderate to severe traumatic brain injury (Level 2). 52  The ASA Task 
Force strongly agreed that RBC are usually unnecessary when the hemoglobin level is 
more than 10g/dL (strongly),  Stainsby et al stated it was rarely indicated when Hb 
>10g/dL (Level 1), and the Australian guideline stated that it is likely inappropriate to 
transfuse at that hemoglobin level unless there are specific indications (Level I). 47,54,55  
However, Ferraris et al stated that it is not unreasonable to transfuse red cells in certain 
patients with clinical non-cardiac end-organ ischemia, such as the central nervous and 
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gastrointestinal system, whose hemoglobin level is as high as 10g/dL (Class 2B, C). 53  
However this statement was modified with the disclaimer that such a “liberal 
transfusion” it is unlikely to improve oxygen transport and is not recommended for 
those purposes (Class 2B, C). 53 
Table 16. Guidelines recommending transfusion threshold of Hb ≠ 10 g/dL 
Organization Recommendation Evidence 
Napolitano (USPTF) Level 2 (reasonable scientific evidence 
and strong expert opinion) 
Class 2, Class 3 (Strong prospective 
and retrospective analysis, 
retrospective data collection) 
Ferraris (ACC/AHA) Class 3 (Conditions for which there is 
evidence and/or general agreement 
that the procedure/treatment is not 
useful/effective, and in some cases 
harmful) 
C (Consensus opinion of experts) 
British Columbia (AHCPR) Grade C (Body of evidence provides 
some support for recommendation but 
care should be take in its application) 
Level IV (Evidence obtained from 
case series, either post-test or 
pretest and post-test) 
New Zealand (NHMRC) 
 
Level I (Evidence obtained from a 
systematic review of all relevant 
RCT) 
ASA Strongly agree Insufficient 
 
 
Recommendations Regarding Clinical Use Fresh Frozen Plasma 
Table 10 demonstrates that a total of 31 of the 107 recommendations were 
relevant to fresh frozen plasma use.  Of the 31 recommendations, table 11 and figure 9 
demonstrate that 7 (22.58%) recommendations were generated from “strong” level of 
evidence, 1 (3.23%) recommendation was generated by “intermediate” level evidence, 
and 23 (74.19%) recommendations generated by “low” level evidence.   
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Figure 9.  Level of Evidence Utilized for Fresh Frozen Plasma Recommendations 
 
 
Of the 31 recommendations, table 12 and figure 10 demonstrate that 9 (29.03%) 
of the recommendations were classified as a “strong,” 10 (32.26%) recommendations 
were classified as an “intermediate,” and 12 (38.71%) recommendations were classified 
as a “weak.”  Of the 9 “strong” recommendations, none of recommendations was based 
on “strong” level of evidence, 3 (33.33%) recommendations based on “intermediate” 
level of evidence, and 6 (66.67%) recommendations based on “low” level of evidence 
(Figure 11). 
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Figure 10.  Strength of Recommendations for Fresh Frozen Plasma 
 
 
Figure 11.  Level of Evidence for “Strong” Recommendations regarding FFP 
 
 
Appendix table 2 summarizes recommendations for the clinical use of fresh 
frozen plasma from the eleven international guidelines.  Six of 10 guidelines mention 
recommendations on the use of fresh frozen plasma, however only 3 of these six 
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guidelines give detailed recommendations on its use.  Three guidelines recommend 
transfusion and treatment with plasma in trauma patients requiring massive transfusion 
(Roback, Moderate) especially to maintain INR and PTT <1.5 (Table 17) or upper limit of 
the reference range or increase fibrinogen level to 1g/L (British Columbia, Grade B Level 
IIB), and to patients with massive bleeding or significant bleeding complicated by 
coagulopathy (PT or aPTT >1.5 control) (Table 17) (Spahn, Grace 1C). 48,57,58  However in 
other trauma settings, Roback et al cannot recommend for or against transfusion of 
plasma at a plasma:RBC ratio of 1:3 or more during massive transfusion (Low) or for the 
use of plasma transfusion in surgical/trauma patients in the absence of massive 
transfusion (Very low). 50 
Table 17. Guidelines recommending transfusion threshold of PT/aPTT >1.5 
Organization Recommendation Evidence 
Spahn (GRADE) Strong / Grade 1 (Recommend; benefits do or 
do not outweigh harm and burden) 
Class C (Low; current evidence from 
observational studies, case series or just 
opinion) 
British Columbia 
(AHCPR) 
Grade C (Body of evidence provides some 
support for recommendation but care should 
be take in its application) 
Level IV (Evidence obtained from case 
series, either post-test or pretest and post-
test) 
 
Roback et al recommended that plasma be transfused in patients with warfarin 
anticoagulation-related intracranial hemorrhage (low), and in the Australian guidelines 
it suggested that transfusion also in the presence of potentially life-threatening bleeding 
(Level IV), but Roback et al cannot recommend for or against transfusion of plasma to 
reverse warfarin anticoagulation in patients without intracranial hemorrhage (very low). 
50,55 
The British Columbian and Australian guidelines give specific recommendations 
regarding congenital and acquired deficiencies.  Fresh frozen plasma is indicated for 
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single factor congenital deficiencies where a specific or combined factor concentrate is 
not available (British Columbia, Grade C Level IV; Australia. Level IV). 48,55  Fresh frozen 
plasma is also indicated for multiple factor deficiencies, hypo/dysfibrinogenemias, 
and/or disseminated intravascular coagulopathy associated with severe bleeding (British 
Columbia, Grade C Level IV; Australia, Level IV). 48,55  Use of fresh frozen plasma for 
treatment of thrombotic thrombocytopenia purpura is controversial, but transfusion of 
fresh frozen plasma may be initiated for treatment (British Columbia, Grade B Level IB; 
Australia Level IV). 48,55  For vitamin K deficiency, fresh frozen plasma should not be used 
to correct inadequate vitamin K intake even if clotting factors are prolonged unless 
urgent invasive procedures are required or the patient is bleeding (British Columbia, 
Grade B Level IIA). 48  With regards to liver disease, especially in the setting of a liver 
biopsy with a patient with marked coagulopathy, the prophylactic use of frozen plasma 
may be utilized prior to a procedure based on the clinician’s judgment (British 
Columbia, Grade B Level IIA; Australia Level IV). 48,55 
In the British Columbia guidelines fresh frozen plasma should not be routinely 
used in cardiopulmonary bypass surgery (British Columbia, Level IIB). The Australian 
guideline recommends the use of frozen plasma only in the presence of bleeding and 
abnormal coagulation following cardiac bypass surgery (Australia, Level IV). 48,55  Fresh 
frozen plasma is generally not considered appropriate for the treatment of 
hypovolemia, plasma exchange procedures or treatment of immunodeficiency states 
(Australia, Level IV). 55 
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 Recommendations Regarding Clinical Use of Platelets 
Table 10 demonstrates that a total of 15 of the 107 recommendations were 
relevant to platelet use.  Of the 15 recommendations, table 11 and figure 12 
demonstrate that 1 (9.67%) recommendation was generated from “strong” level of 
evidence, no recommendation was generated by “intermediate” level of evidence, and 
14 (93.33%) recommendations were generated by “low” level of evidence.   
Figure 12.  Level of Evidence Utilized for Platelet Recommendations 
  
Table 12 and figure 13 demonstrate that 10 (66.67%) recommendations were 
classified as “strong” recommendations, no recommendations were classified as an 
“intermediate”, and 5 (33.33%) recommendations were classified as “weak” 
recommendations. Of the 10 “strong” recommendations, 1 (10.00%) recommendation 
was based on “strong” level of evidence, and 9 (90.00%) recommendations based on 
“low” level of evidence (Figure 14).  
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Figure 13.  Strength of Recommendations for Platelets 
 
Figure 14.  Level of Evidence for “Strong” Recommendations regarding use of Platelets 
 
Appendix table 3 summarizes the eleven international guideline 
recommendations for the clinical use of platelets.  Four of the 10 guidelines reviewed 
commented in the use of platelets with varying triggers for transfusion.  Dellinger et al 
weakly recommended administering platelets when counts <5,000/mm3 regardless of 
bleeding, counts 5,000-30,000/mm3 if there is a significant bleeding risk, and 
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</=50,000/mm3 if prior to surgery or invasive procedures (Level 2D Weak). 56  The 
Australian guideline also recommends maintaining counts >50,000/mm3 for patients 
undergoing surgery or invasive procedures (Australia, Level IV), counts >50,000/mm3 in 
the setting of massive hemorrhage (Australia, Level IV), and counts >100,000/mm3 in 
presence of diffuse microvascular bleeding (Australia, Level IV). 55 
There are similar platelet transfusion thresholds recommendations for patients 
with trauma or brain injury.  The British Committee recommends maintaining a count 
>75,000/mm3 in for a majority of patients, with a higher target count of 100,000/mm3 
for patients with multiple high-velocity trauma or central nervous system injury (British, 
Level IV Grade C).59  Moreover, Spahn et al recommends administering platelets for a 
count >50,000/mm3 for a majority of patients (Grade 1C), and counts >100,000/mm3 for 
patients with multiple trauma who are severely bleeding or have traumatic brain injury 
(Grade 2C). 51 
As prophylaxis, the Australian guideline recommends transfusion if counts 
<10,000/mm3 in bone marrow failure without risk factors, or counts <20,000/mm3 in the 
presence of bone marrow failure with risk factors (e.g., fever, antibiotics, systemic 
hemostatic failure) (Level II). 55  They also state that platelets are not generally 
considered appropriate to treat immune-mediated platelet destruction, thrombotic 
thrombocytopenia purpura, hemolytic uremic syndrome, or drug-induced or cardiac-
bypass-induced thrombocytopenia without hemorrhage (Level IV). 55 
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Recommendations Regarding Clinical Use of Cryoprecipitate 
Table 10 demonstrates that a total of 13 of the 107 recommendations were 
relevant to packed red blood cell use.  Of the 13 recommendations, table 11 and figure 
15 demonstrate that no recommendations was generated from “strong” level of 
evidence or “intermediate” level evidence, and all 13 (100.00%) recommendations were 
generated by “low” level of evidence.   
Figure 15.  Level of Evidence Utilized for Cryoprecipitate Recommendations 
 
Table 12 and figure 16 demonstrate that 7 (53.85%) recommendations were 
classified as “strong” recommendations, 5 (38.46%) recommendations were classified as 
“intermediate,” and 1 (7.69%) recommendation was classified as a “weak” 
recommendation.  All 7 “strong” recommendations regarding use of cryoprecipitate 
were based on “low” level of evidence. 
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Figure 16.  Strength of Recommendations for Cryoprecipitate 
 
Appendix table 4 summarizes recommendations for the clinical use of 
cryoprecipitate from the eleven international guidelines.  Four of 10 guidelines mention 
indications and recommendations for the use of cryoprecipitate.  Three of the guidelines 
specify that the transfusion threshold for cryoprecipitate should be used to maintain 
fibrinogen >1g/L (British, Grade C Level IV; British Columbia, Grade C Level I; Spahn, 
Grade 1C).51,60  The use of transfusion is considered appropriate in patients with 
fibrinogen deficiency, inherited or acquired hypofibrinogenemia, dysfibrinogenemia or 
disseminated intravascular coagulation where there is clinical bleeding, during an 
invasive procedure, or trauma (British Columbia, Grade C Level IV; Australia, Level IV; 
Spahn, Grade 1C). 51,55,60 
All guidelines advocate the use of cryoprecipitate in the setting of hemophilia, 
von Willebrand’s disease, or deficiencies or factor XIII or fibronectin.  The advisory group 
of British Columbia recommends that cryoprecipitate can be used in patients with von 
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Willebrand’s disease if they are unresponsive to desmopressin (British Columbia, Grade 
C, Level IV), used in hemophilia A patients in areas where Factor VIII:C concentrates are 
not available (British Columbia, Level IV), and use in patients with FXIII deficiency where 
specific factor concentrate is usually not readily available in emergent situations (British 
Columbia, Grade C, Level IV). 60  The Australian guideline also does not generally 
consider it appropriate to use cryoprecipitate in the treatment of hemophilia, von 
Willebrand’s disease, or deficiencies of factor XIII or fibronectin unless alternative 
therapies are unavailable (Level IV). 55 
In addition, clinical algorithms incorporate the use of cryoprecipitate to manage 
signs or symptoms of intracranial bleeding in patients during or after administration of 
tPA (British Columbia, Grade C Level IV). 60  Cyroprecipitate is not recommended in 
sepsis, as recent controlled trials failed to improve renal and pulmonary function and 
peripheral hemodynamics in critically ill septic patients (British Columbia, Grade A Level 
IV), and is not recommended in the use of preparation for fibrin glue (British Columbia, 
Grade B and C Level III and IV). 60 
 
Discussion 
Guidelines Working Group Panel 
 Analysis of the guidelines demonstrates that a significant proportion of the 
guidelines do not mention the total number of members involved, members 
representing different medical and surgical specialties or societies, and consulting 
methodologists comprising the guideline working group (Table 5, Table 6, Figure 1, and 
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Figure 2).    The majority of the guidelines reviewed list the medical and surgical 
specialties represented in their working group (Table 5 and 6).  Only half of the 
guidelines specified medical specialties such as hematology and internal 
medicine/critical care medicine in their methods (Table 6 and figure 2).  However, only a 
minority of the guidelines’ working group panels included members trained in 
anesthesiology, emergency medicine, surgery (thoracic/trauma) or obstetrics.  The 
inclusion of such specialties is important as physicians in those fields frequently deal 
with patients who can present or develop significant bleeding and require massive 
transfusion. It is important to note that there was no mention of members in the 
working panel representing orthopedic surgery, vascular surgery, oncologic surgery, 
solid organ transplant surgery and neurosurgery.  The exclusion of these surgical 
subspecialties is significant, as members of these specialties regularly use transfusion of 
blood components. It is important to include them, to get their perspective, give 
credibility to the guidelines and for the uniformity in clinical care. 
More surprisingly, there is even less inclusion of methodologists in the process of 
guideline development.  Only two of eleven guidelines specifically mention that they 
consulted methodologists and included them in their working group (Table 5).  It is vital 
to know if methodologists are involved in the process of guideline development, as they 
are trained in critically appraising evidence, such as assessing the significance of 
outcomes and factors affecting quality of evidence.  In addition, methodologists are also 
trained in determining the applicable translation of the evidence in to clinical practice 
and grading strength of recommendations, such as assessing risks versus benefits.  
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Evidence and Systematic Reviews Utilized to Generate Guidelines 
 There is a lack of clarity in the methods section about the nature of literature 
review employed by the eleven guidelines (Table 7 and 8).  A majority of guidelines did 
not reveal the databases utilized for their literature search or mention the study designs 
of the evidence they utilized to base their recommendations.   
 
Methodology Utilized to Grade Evidence 
The six methodologies employed by the eleven international guidelines reviewed 
have both their merits and their limitations.  The details of the inclusion criteria and 
definitions for classification of grading quality of evidence and strength of 
recommendations for each methodology as listed below (Tables 18-32).   
Table 18. AHRQ Grading of Quality of Evidence 
Grade Definition 
1a Evidence obtained from meta-analysis of RCT 
1B Evidence obtained from at least one RCT 
2A Evidence obtained from at least one well-designed controlled study without randomization 
2B Evidence obtained from at least one other type of well-designed quasi-experimental study 
3 Evidence obtained from well-designed non-experimental descriptive studies, such as 
comparative studies, correlation studies and case studies 
4 Evidence obtained from expert committee reports or opinions and/or clinical experiences of 
respected authorities 
 
Table 19. AHRQ Strength of Recommendations 
Strength Definition 
A Requires at least one RCT as a part of a body of literature of overall good quality 
and consistency addressing specific recommendation. 
(Evidence levels 1A, 1B) 
B Requires the availability of well conducted clinical studies but no RCT on the 
topic of recommendation 
(Evidence levels 2A, 2B, 3) 
C Requires evidence obtained from expert committee reports or opinions and/or 
clinical experiences of respected authorities.  Indicates an absence of directly 
applicable clinical studies of good quality. 
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 The USPSTF methodology involves reviewing evidence, estimating the 
magnitude of benefits and harms for each preventive service, reaching a conclusion 
about the net benefit for each preventive service, and issuing a recommendation about 
the service(Tables 20-23).  This methodology does not include the type of study design 
as a factor influencing grading of evidence or provide recommendations when there is 
little or low evidence available.   
Table 20. USPSTF Grading Definition After May 2007 
Grade Definition Recommendation 
A Recommends the service.  There is high 
certainty that the net benefit is 
substantial. 
Offer or provide this service. 
B Recommends the service.  There is high 
certainty that the net benefit is 
moderate or there is moderate certainty 
that the net benefit is moderate to 
substantial. 
Offer or provide this service. 
C Recommends against routinely 
providing the service. There may be 
considerations that support providing 
the service in an individual patient. 
There is at least moderate certainty that 
the net benefit is small. 
Offer or provide this service only if other 
considerations support the offering or 
providing the service in an individual 
patient. 
D Recommends against the service. There 
is moderate or high certainty that the 
service has no net benefit or that the 
harms outweigh the benefits. 
Discourage the use of this service. 
I Concludes that the current evidence is 
insufficient to assess the balance of 
benefits and harms of the service. 
Evidence is lacking, of poor quality, or 
conflicting, and the balance of benefits 
and harms cannot be determined. 
If the service is offered, patients should 
understand the uncertainty about the 
balance of benefits and harms. 
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Table 21.  USPSTF Level of Certainty After May 2007 
Level of Certainty Definition  
High The available evidence usually includes consistent results from well-designed, well-conducted 
studies in representative primary care populations. These studies assess the effects of the 
preventive service on health outcomes. This conclusion is therefore unlikely to be strongly 
affected by the results of future studies. 
Moderate The available evidence is sufficient to determine the effects of the preventive service on 
health outcomes, but confidence in the estimate is constrained by such factors as: 
 The number, size, or quality of individual studies. 
 Inconsistency of findings across individual studies. 
 Limited generalizability of findings to routine primary care practice. 
 Lack of coherence in the chain of evidence. 
As more information becomes available, the magnitude or direction of the observed effect 
could change, and this change may be large enough to alter the conclusion. 
Low The available evidence is insufficient to assess effects on health outcomes. Evidence is 
insufficient because of: 
 The limited number or size of studies. 
 Important flaws in study design or methods. 
 Inconsistency of findings across individual studies. 
 Gaps in the chain of evidence. 
 Findings not generalizable to routine primary care practice. 
 Lack of information on important health outcomes. 
More information may allow estimation of effects on health outcomes. 
 
 
Table 22. USPSTF Grading Definition Prior to May 2007 
 
Grade Definition Recommendation 
A Strongly recommends that clinicians provide [the 
service] to eligible patients. The USPSTF found 
good evidence that [the service] improves 
important health outcomes and concludes that 
benefits substantially outweigh harms. 
Strongly recommended. 
B Recommends that clinicians provide [the service] 
to eligible patients. The USPSTF found at least 
fair evidence that [the service] improves 
important health outcomes and concludes that 
benefits outweigh harms. 
Recommended. 
C Makes no recommendation for or against routine 
provision of [the service]. The USPSTF found at 
least fair evidence that [the service] can improve 
health outcomes but concludes that the balance 
of benefits and harms is too close to justify a 
general recommendation. 
No recommendation. 
D Recommends against routinely providing [the 
service] to asymptomatic patients. The USPSTF 
found at least fair evidence that [the service] is 
ineffective or that harms outweigh benefits. 
Not recommended. 
I Concludes that the evidence is insufficient to 
recommend for or against routinely providing 
[the service].Evidence that the [service] is 
effective is lacking, of poor quality, or conflicting 
and the balance of benefits and harms cannot be 
determined. 
Insufficient evidence to make 
recommendation. 
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Table 23. USPSTF Quality of Evidence Prior to May 2007 
 
Quality of Evidence Definition 
Good  Evidence includes consistent results from well-designed, well-conducted studies in 
representative populations that directly assess effects on health outcomes. 
Fair  Evidence is sufficient to determine effects on health outcomes, but the strength of 
the evidence is limited by the number, quality, or consistency of the individual 
studies, generalizability to routine practice, or indirect nature of the evidence on 
health outcomes. 
Poor Evidence is insufficient to assess the effects on health outcomes because of 
limited number or power of studies, important flaws in their design or conduct, 
gaps in the chain of evidence, or lack of information on important health 
outcomes. 
 
The ACC/AHA methodology in Table24 involves collection and grading of 
evidence for guideline development, which allows one to draw conclusions (i.e., 
guideline recommendations) that are supported by data (i.e., level of evidence).  The 
ACC/AHA Task Force recommends either assigning the Classification of 
Recommendation and Level of Evidence when writing the recommendations, or rather 
to state the recommendation and assign the classification afterwards after re-examining 
data.  Assigning a Classification of Recommendation and Level of Evidence, aids to 
provide a more descriptive and quantitative criteria for evidence ratings.  In addition, 
with the ACC/AHA methodology involving Classification of Recommendations and Levels 
of Evidence, any combination of the two rating systems is possible.   
Designation of Level of Evidence B or C should not be construed as implying that 
the recommendation is weak.  It merely implies that certain clinical questions addressed 
in the guidelines do not lend themselves to experimentation or have not yet been 
addressed by high quality investigations.  The clinical questions may be relevant or 
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important enough that it is addressed in the guidelines, even though randomized 
controlled studies may not be available to answer and support the query. 
Table 24. AHA/ACC Grading of Evidence and Strength of Recommendation 
Classification 
 Size of Treatment Effect 
Estimate of 
Certainty 
(Precision) 
of 
Treatment 
Effect 
 Class I 
 
Benefit >>>Risk 
 
Procedure/Treatment 
SHOULD be 
performed/administered 
Class IIA 
 
Benefit>>>Risk 
 
Additional studies with 
focused objectives 
needed 
 
IT IS REASONABLE to 
perform 
procedure/administer 
treatment 
Class IIB 
 
Benefit ≥ Risk 
 
Additional studies with 
broad objectives needed; 
additional registry data 
would be helpful 
 
IT IS NOT UNREASONABLE 
to perform 
procedure/administer 
treatment 
Class III 
 
Risk ≥ Benefit 
 
Procedure/Treatment 
should NOT be 
performed/administered 
since IT IS NOT HELPFUL 
and MAY BE HARMFUL 
Level A  
 
Multiple (3-5) population 
risk strata evaluated 
 
General consistency of 
direction and magnitude 
of effect 
Recommendation that 
procedure or treatment is 
useful/effective 
 
Sufficient evidence from 
multiple randomized trials 
or meta-analyses 
Recommendation in 
favor of treatment or 
procedure being 
useful/effective 
 
Some conflicting 
evidence from multiple 
randomized trials or 
meta-analyses 
Recommendation’s 
usefulness/efficacy less 
well established 
 
Greater conflicting 
evidence from multiple 
randomized trials or meta-
analyses 
Recommendation that 
procedure or treatment 
not useful/effective and 
may be harmful 
 
Sufficient evidence from 
multiple randomized 
trials or meta-analyses 
Level B 
 
Limited (2-3) population 
risk strata evaluated 
Recommendation that 
procedure or treatment is 
useful/effective 
 
Limited evidence from 
single randomized trial or 
non-randomized studies 
Recommendation in 
favor of treatment or 
procedure being 
useful/effective 
 
Some conflicting 
evidence from single 
randomized trial or non-
randomized studies 
Recommendation’s 
usefulness/efficacy less 
well established 
 
Greater conflicting 
evidence from single 
randomized trial or non-
randomized studies 
Recommendation that 
procedure or treatment 
not useful/effective and 
may be harmful 
 
Limited evidence from 
single randomized trial 
or non-randomized 
studies 
Level C 
 
Very limited (1-2) 
population risk strata 
evaluated 
Recommendation that 
procedure or treatment is 
useful/effective 
 
Only expert opinion, case 
studies, or standard-of-
care 
Recommendation in 
favor of treatment or 
procedure being 
useful/effective 
 
Only diverging expert 
opinion, case studies, or 
standard –of-care 
Recommendation’s 
usefulness/efficacy less 
well established 
 
Only diverging expert 
opinion, case studies, or 
standard-of-care 
Recommendation that 
procedure or treatment 
not useful/effective and 
may be harmful 
 
Only expert opinion, 
case studies, or 
standard-of-care 
 
The NHMRC utilizes a system that allows also for Levels of Evidence and Grades 
of Recommendation (Tables 25 and 26).  The classification system for evidence assigns 
levels of evidence according to the type of research question, recognizing the 
importance of appropriate research design to that specific clinical question in guideline 
development.  Grading of recommendations is ascribed not only by the level of 
evidence, but takes into consideration the quality of the study and the likelihood that 
the results have been affected by bias during its conduct, the consistency of its findings 
to those from other studies, the clinical impact of its results, and generalizability of the 
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results to the population for whom the guideline is intended, and the applicability of the 
results to the Australian or local healthcare system.  Thus the grade of the 
recommendation is based on an overall assessment of all these components of the body 
of evidence being assessed. 
Table 25. NHMRC Evidence Hierarchy 
 
LEVEL Intervention Diagnostic Accuracy Prognosis Etiology Screening 
Intervention 
I A systematic review 
of level II studies 
A systematic review 
of level II studies 
A systematic review 
of level II studies 
A systematic review 
of level II studies 
A systematic review 
of level II studies 
II A randomized 
controlled trial 
A study of test 
accuracy with: an 
independent, 
blinded comparison 
with a valid 
reference standard, 
among consecutive 
persons with a 
defined clinical 
presentation 
A prospective cohort 
study 
A prospective cohort 
study 
A randomized 
controlled trial 
III1 A pseudo-
randomized 
controlled trial (ie, 
alternate allocation 
or some other 
method 
A study of test 
accuracy with: an 
independent, 
blinded comparison 
with a valid 
reference standard, 
among non-
consecutive persons 
with a defined 
clinical presentation 
All or none All or none A pseudo-
randomized 
controlled trial (ie, 
alternate allocation 
or some other 
method) 
III2 A comparative 
study with 
concurrent controls: 
Non-randomized 
experimental trial, 
Cohort study, 
Case-control study, 
Interrupted time 
series with a control 
group 
A comparison with 
reference standard 
that does not meet 
the criteria required 
for Level II and III1 
evidence 
Analysis of 
prognostic factors 
amongst persons in a 
single arm of 
randomized 
controlled trial 
A retrospective 
cohort study 
A comparative study 
with concurrent 
controls: 
Non-randomized 
experimental trial, 
Cohort study, Case-
control study 
III3 A comparative 
study without 
concurrent controls: 
Historical control 
study, 
Two or more single 
arm study, 
Interrupted time 
series without a 
parallel control 
group 
Diagnostic case-
control study 
A retrospective 
cohort study 
A case-control study A comparative study 
without concurrent 
controls: 
Historical control 
study, 
Two or more single 
arm study 
IV Case series with 
either post-test or 
pre-test/post-test 
outcomes 
Study of diagnostic 
yield (no reference 
standard) 
Case series, or cohort 
study of persons at 
different stages of 
disease 
A cross-sectional 
study or case series 
Case series 
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Table 26. NHMRC Body of Evidence Matrix and Grades of Recommendation 
 
Component Grade A 
 
Excellent 
 
Body of 
evidence can be 
trusted to guide 
practice 
Grade B 
 
Good 
 
Body of evidence 
can be trusted to 
guide practice in 
most situations 
Grade C 
 
Satisfactory 
 
Body of evidence 
provides some 
support for 
recommendations 
but care should be 
taken in its 
application 
Grade D 
 
Poor 
 
Body of evidence is 
weak and 
recommendation 
must be applied with 
caution 
Evidence Base One or more 
level I studies 
with a low risk 
or bias or 
several level II 
studies with a 
low risk bias 
One or two level II 
studies with a low 
risk of bias or a 
systematic 
review/several 
level III studies 
with low risk bias 
One or two level III 
studies with a low 
risk of bias, or level I 
or II studies with a 
moderate risk of bias 
Level IV studies, or 
level I to III 
studies/systematic 
reviews with a high 
risk of bias 
Consistency All studies 
consistent 
Most studies 
consistent and 
inconsistency may 
be explained 
Some inconsistency 
reflecting genuine 
uncertainty around 
clinical questions 
Evidence is 
inconsistent 
Clinical Impact Very large Substantial Moderate Slight or restricted 
Generalizability Population/s 
studied in body 
of evidence are 
the same as the 
target 
population for 
the guideline 
Population/s 
studied in the 
body of evidence 
are similar to the 
target population 
for the guideline 
Population/s studied 
in body of evidence 
differ to target 
population for 
guideline but it is 
clinically sensible to 
apply this evidence 
to target population 
Population/s studied 
in body of evidence 
differ to target 
population and hard 
to judge whether it is 
sensible to generalize 
to target population 
Applicability Directly 
applicable to 
Australian 
healthcare 
context 
Applicable to 
Australian 
healthcare context 
with few caveats 
Probably applicable 
to Australian 
healthcare context 
with some caveats 
Not applicable to 
Australian healthcare 
context 
 
The ASA uses specific terms to specify the grading of evidence in their 
formulation of recommendations.  When sufficient numbers of studies are available for 
evaluation, the terms in table 27 are used to describe the strength of the findings.  
When the ASA describes the lack of scientific evidence in the literature, it uses the terms 
listed in table 28.  When information is collected from consultants and members of the 
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ASA, the terms used to describe survey responses for any issue are represented in Table 
29.  The survey responses are solicited on a five-point scale, ranging from 1 (strongly 
disagree) to 5 (strongly agree), with the score of 3 being equivocal.  
Table 27. ASA Grading of Evidence 
Support Meta-analysis of a sufficient number of randomized controlled trials indicates a 
statistically significant relationship (P<0.01) between a clinical intervention and a 
clinical outcome. 
Suggest Information from case reports and descriptive studies permits inference of a 
relationship between an intervention and an outcome.  This type of qualitative 
information does not permit a statistical assessment of significance. 
Equivocal Qualitative data are not adequate to permit inference of a relationship between an 
intervention and an outcome and (1) there is insufficient quantitative information 
or (2) aggregated comparative studies have found no significant differences among 
groups or conditions. 
 
Table 28. ASA Strength of Recommendations 
Silent No identified studies address the relationship of interest. 
Insufficient There are too few published to investigate a relationship between an intervention 
and outcome. 
Inadequate The available studies cannot be used to assess the relationship between an 
intervention and an outcome.  There studies either do not meet the criteria for 
content as defined in the Focus of these Guidelines or do not permit a clear casual 
interpretation of findings due to methodologic concerns. 
 
Table 29. ASA Survey Responses 
Strongly Agree Median score of 5 (at least 50% of the responses are 5). 
Agree Median score of 4 (at least 50% of the responses are 4 or 4 and 5). 
Equivocal Median score of 3 (at least 50% of the responses are 3, or no other response 
category or combination of similar categories contain at least 50% of the 
responses). 
Disagree Median score of 2 (at least 50% of responses are 2 or 1 and 2). 
Strongly Disagree Median score of 1 (at least 50% of responses are 1). 
  
The GRADE methodology, however, has become the methodology that is 
currently being accepted by an increasing number of organizations.  The GRADE working 
group represents an international collaboration of guideline developers, clinicians, 
health service researchers, and methodologists.  The GRADE system for grading the 
P a g e  | 50 
 
 
 
quality of evidence comprises four steps: identifying important and critical outcomes; 
preliminary grading of evidence in terms of study design, quality, consistency and 
directness; taking in to account other factors that can increase or decrease evidence; 
and the overall quality of the evidence.  The definition for quality of evidence is listed in 
Table 30.  The strength of recommendation, categorized as strong, weak or conditional 
recommendations for or against an intervention or treatment, is defined as the extent 
to which one can be confident that the desirable effects of an intervention outweigh the 
undesirable effects.  It requires the consideration of the benefits and risks of an 
intervention for all patient-important endpoints, the associated values and preferences 
and resource use.   
Other previous systems of grading rely almost exclusively on overall study design 
to determine quality of evidence, however in the GRADE system study design remains 
critical but not a sole factor in judging the quality of evidence.  In the GRADE system, 
expert opinion is not a category of quality of evidence but rather an interpretation of 
existing evidence.  In addition there are factors that can reduce or increase quality of 
evidence for each study design, that overcome the limitations of grading quality of 
evidence with just study design (Tables 31 and 32).  This is important, as a well-designed 
and executed non-randomized trial or observational study, may provide better quality 
evidence than a poorly executed randomized-controlled trial. 
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Table 30. GRADE Quality of Evidence 
Grade Definition 
High 
⊕⊕⊕⊕  
Further research is unlikely to change our confidence in the estimate of effect. 
Moderate 
⊕⊕⊕  
Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate. 
Low 
⊕⊕  
Further research is very likely to have an important impact on our confidence in 
the estimate of effect and is likely to change the estimate. 
Very Low 
⊕  
Any estimate of effect is very uncertain. 
 
Table 31. Factors that can reduce the Quality of the Evidence 
Factor Consequence 
Limitations in study design or execution (risk of bias) ↓ 1 or 2 levels 
Inconsistency of results ↓ 1 or 2 levels 
Indirectness of evidence ↓ 1 or 2 levels 
Imprecision ↓ 1 or 2 levels 
Publication bias ↓ 1 or 2 levels 
 
Table 32.  Factors that can increase the Quality of the Evidence 
Factor Consequence 
Large magnitude of effect ↑ 1 or 2 levels 
All plausible confounding would reduce the demonstrated effect or 
increase if no effect was observed 
↑ 1 level 
Dose-response gradient ↑ 1 level 
 
The advantage of the GRADE system versus other methodologies is its 
transparency.  It considers many other factors other than study design of literature in 
determining the strength and quality as evidence.  In addition, it generates appropriate 
recommendations for course of action in the setting of very little evidence available.  
Some of the medical professional associations that have shifted to using the GRADE 
system include the following international organizations listed in Appendix table 5. 
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Practice Guideline Recommendations 
 Almost half (48.86%) of the total recommendations reviewed pertain only to the 
transfusion of packed red blood cells (Table 10 and figure 3).  The rest of the 
recommendations reviewed pertain to coagulation blood components such as fresh 
frozen plasma (28.97%), platelets (12.02%), and cryoprecipitate (12.15%).  This suggests 
that there is mounting literature regarding the transfusion of packed red blood cells, but 
substantial evidence is still lacking regarding the appropriate use and safety of fresh 
frozen plasma, platelets, and cryoprecipitate. 
 Of the 107 recommendations reviewed, a majority (65.42%) of the 
recommendations were based from “low” level of evidence.  This “low” level of 
evidence may include case series or reports, expert reports or opinions, and evidence 
that is limited in power or demonstrates flaws in the study design.  Only 12 (11.21%) 
recommendations are based on “strong” level of evidence, such as meta-analyses and 
randomized controlled trials.  Our analysis suggests the lack of relationship/association 
between the quality of evidence reviewed and the strength of recommendations 
generated by the guideline working panels (Table 11, Table 12, Figure 4, Figure 5).  
Though 82 (76.63%) recommendations are classified as “strong” or “intermediate” 
recommendations, they are based solely on “low” level of evidence (Table 12, Figure 5).  
 
Recommendations Regarding Clinical Use of Blood Products 
A majority (85.41%) of recommendations for packed red blood cells deemed as 
“strong” and “intermediate” are based almost entirely (91.67%) on “intermediate” and 
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“low” level of evidence.  Of the “strong” recommendations regarding the use of packed 
red blood cells, majority were based on a “low” level of evidence.  More than half 
(61.29%) of recommendations for fresh frozen plasma deemed “strong” and 
“intermediate” are based exclusively (74.19%) on “low” level of evidence. All 
recommendations pertaining to cryoprecipitate transfusion are based solely on “low” 
level of evidence.  A majority of “strong” recommendations for platelet transfusion are 
based almost entirely (93.33%) on “low” level evidence.  With the slight exception of 
packed red blood cells, all guidelines undividedly reported “strong” and/or 
“intermediate” recommendations to transfuse coagulation products on the basis of 
“low” level evidence.  
In addition, there was multiple hemoglobin level transfusion triggers are 
reported amongst the eleven guidelines, and even within a guideline.  There was clearly 
a discrepancy between guideline recommendations about transfusing for a particular 
hemoglobin level, as well as, a discrepancy between the quality and strength of 
evidence to support the recommendation.  For example in regard to use of 6g/dL of 
hemoglobin as a packed red blood cell transfusion trigger, the two organizations utilized 
the same quality of evidence (consensus opinions of experts) yet generated different 
recommendations.  One organization favored the use and efficacy of the intervention, 
while the other organization gave the intervention its lowest level of 
recommendation.53,54   
In addition, one organization reported two different hemoglobin levels as 
transfusion triggers in the context of different clinical settings.53  Both recommendation 
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statements were based on “consensus opinions of experts.”  The recommendation to 
transfuse at hemoglobin < 6g/dL is graded Class 2A supporting the intervention in favor 
of its usefulness and efficacy, whereas the recommendation to transfuse at hemoglobin 
< 7g/dL is graded Class 2B giving weaker support to the recommendation as the 
usefulness and efficacy.  It is unclear through analysis of these eleven guidelines what 
specific hemoglobin level should be utilized as the threshold hemoglobin level to trigger 
transfusion of packed red blood cells. The only consensus is not to transfuse if the Hb is 
> 10gm/dl.  
The recommendations generated for the use of fresh frozen plasma, platelets, 
and cryoprecipitate are based on even weaker level of evidence compared to the 
recommendations generated for use of packed red blood cells.  The recommendations 
for coagulation products are insufficient, both in number of total recommendations and 
in strength of recommendations. Two organizations have stated a definite threshold to 
transfuse fresh frozen plasma (PT or aPTT is > 1.5 normal). 58,61  However, the data come 
from the same quality of evidence (case series, observational studies, and consensus 
opinion of experts). In the eleven guidelines we evaluated, there is no consensus 
regarding a definite platelet level or a fibrinogen which should trigger transfusion.  
 
Limitations of Study 
The following are the limitations of this investigation.  Of the guidelines included, 
only guidelines published in the English language were reviewed, as well as, only 
guidelines published in the last ten years were reviewed.  We have only reviewed 
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guidelines relevant to adult patients.  In addition, only two reviewers screened the initial 
literature searches performed on PubMed/Medline, Scopus, Cochrane Central and the 
National Guideline Clearinghouse, and determined that the final eleven guidelines to be 
selected for inclusion in the study. 
In order to compare different guidelines we had to develop a uniform scoring 
system. These definitions were created to readily compare the eleven guidelines that 
had all used different grading and classification methodology systems.  However, this 
scoring system has not been externally validated and is kind of unique. However we feel 
that the system is valid as it generally encompasses and closely follows the definitions 
that were used by the original seven methodologies.  
 
Implications of Study 
 Analysis of these eleven international guidelines suggests that currently a 
large body of recommendations concerning blood component therapy is based solely on 
“low” quality evidence.  Clearly there is a significant scarcity of strong evidence as well 
as clearly explicit recommendations to guide clinician practice of transfusion of blood 
products.  In addition, many of the guidelines are not clear in reporting their methods of 
literature search, working group composition, and evidence review process.  There is 
also a lack of consistency in current guidelines’ use of evidence grading methodologies. 
This adds confusion to the interpretation of the recommendations generated for 
clinicians and applications of guidelines.   
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The use of different grading methodologies generates discrepancies in 
recommendations.  The use of multiple and different grading methodologies does not 
allow for clinicians to readily compare recommendations generated from guidelines.  In 
addition, each methodology systems assigns quality of evidence based on a variety of 
factors and thus can result in varying strength of recommendations for the same 
intervention even though derived from the similar data.  These multiple 
recommendations with varying strengths from guidelines can translate to 
inconsistencies in practices amongst practitioners.   
This study demonstrates that there currently is lack of robust and 
methodologically clear transfusion guidelines. Quality randomized controlled trials 
should be conducted especially with regards to the appropriate use and safety of fresh 
frozen plasma, cryoprecipitate and platelets.  In addition, the use of multiple evidence 
grading methodologies creates discrepancies in recommendations and confusion 
amongst clinicians.  Under these circumstances, it seems logical that future directions 
with guideline development should be aimed at the utilization of a universal 
methodology system to grade evidence and classify recommendations.  Moreover, there 
should be more integration of surgical subspecialty physicians in working group panels 
in the development of guideline recommendations.  In conclusion, future research 
should also be stimulated and directed at providing more abundant and high quality 
evidence regarding the use and safety of blood components in the perioperative setting. 
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Appendix  
Appendix Table 1.  Summary of Guideline Recommendations and Indications for 
Clinical Use of Packed Red Blood Cells 
 Napolitano Dellinger Ferraris Spahn British 
Columbia 
ASA New Zealand 
Methodology USPTF GRADE ACC/AHA GRADE AHCPR ASA NHMRC 
Trigger Hb < 7g/dl 
Hb </= 8 g/dl 
Hb < 7g/dl 
Target Hb 7-9 g/dl 
Hb < 6 g/dl 
Hb < 7g/dl 
Target Hb 7-9 
g/dl 
Hb < 6 g/dl 
Maintain at 
Hb > 8g/dl 
Rarely >10 
g/dl 
Hb <6g/dl Hb < 7 g/dl  
(if asymptomatic 
lower trigger 
appropriate) 
Target Hb 7-10 g/dl 
Hemorrhagic shock Hb < 7g/dl Acute 
hemorrhage, 
hemodynamic 
instability or 
inadequate oxygen 
delivery (except in 
acute myocardial 
ischemia) 
 
Level 1: Class 1 RCT, 
strong Class 2 
Observational, Pro 
Cohort, prevalence, 
case-control 
retrospective 
 
Hb < 7g/dl 
For acute 
hemorrhage, 
higher Hg level 
may be required 
     
Critically 
ill/mechanical 
ventilation 
Hb < 7g/dl Patients 
with stable cardiac 
disease 
Avoid Hb as trigger 
 
Level 2: Class 2, Class 
3 
      
Myocardial 
ischemia/cardiac 
disease 
Acute coronary 
disease and anemia 
use trigger of Hb </= 
8 g/dl 
 
Level 3 
Hb < 7g/dl 
Higher Hb level 
may required 
     
Post-operative   Hb < 6 g/dl 
For cardiac 
operations 
 
Hb < 7 g/dl 
No high-level 
evidence 
    
Cardiopulmonary 
bypass 
  Hb < 6 g/dl 
Except in patients 
with cardiovascular 
disease, diabetes 
mellitus, 
cerebrovascular 
disease, carotid 
stenosis 
 
Hb target >/= 7 g/dl 
For patients at risk 
for critical end-organ 
ischemia 
    
Lactic acidosis  Hb < 7g/dl 
Higher Hb level 
may required 
     
Not indicated Sepsis (no clear 
evidence transfusion 
increases tissue 
oxygenation) 
Traumatic brain 
injury and 
intracranial 
hemorrhage (no 
clear evidence it 
improves outcomes) 
 
 Unlikely to improve 
tissue pxygenation 
with Hb > 10 g/dl 
  Hb 
>10g/dl 
Inappropriate when 
Hb > 10 g/dl 
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Appendix Table 2: Summary of Guideline Recommendations and Indications for 
Clinical Use of Fresh Frozen Plasma 
 Roback Dellinger Spahn British 
Columbia 
ASA New Zealand 
Methodology GRADE GRADE GRADE AHCPR ASA NHMRC 
Trigger - - PT/aPTT < 
1.5 
PT/aPTT < 1.5 Elevate
d aPTT 
(agree) 
- 
Massive transfusion   For massive 
or significant 
bleeding 
complicated 
by 
coagulopath
y 
INR/PTT < 1.5 
Fibrinogen >/= 
1.0 g/L 
Replacement of 
patient’s whole 
blood volume 
within 24 hours 
  
Trauma Suggests for 
massive 
transfusion 
     
Inherited deficiencies    In emergency  Recommended 
before high-risk 
procedures 
DIC    Only with active 
bleeding and 
coagulation abnl 
 Recommended 
TTP    As interim 
measure, a slow 
infusion 
 Recommended 
Warfarin 
anticoagulation/intracrani
al hemorrhage 
Suggests 
transfusion 
  Severe bleeding 
or hemostasis 
for emergency 
surgery or 
invasive 
procedure 
 For immediate 
reversal in 
presence of life-
threatening 
bleeding 
Vitamin K deficiency    Bleeding or 
urgent invasive 
procedure 
  
Liver biopsy    Prophylactic 
measure is 
there is marked 
abnl or 
coagulopathy 
  
Not indicated Acute 
pancreatitis, 
organophosphat
e poisoning, 
coagulopathy 
associated with 
acetaminophen 
overdose, 
intracranial 
hemorrhage 
after severe 
closed head 
injury without 
coagulopathy, 
nonsurgical non 
cardiac patients 
in ICU 
To correct 
lab clotting 
abnormalit
y unless 
bleeding is 
present or 
planned 
invasive 
procedure 
 Cardiopulmonar
y bypass 
Invasive bedside 
procedures with 
mild to 
moderate abnl 
 Hypovolemia, 
plasma exchange 
procedures, 
treatment of 
immunodeficienc
y states 
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Appendix Table 3: Summary of Guideline Recommendations and Indications for 
Clinical Use of Platelets  
 Dellinger Spahn British 
Columbia 
ASA New Zealand 
Methodology GRADE GRADE AHCPR ASA NHMRC 
Trigger < 5000/mm3 
regardless of 
bleeding 
<50000/mm3 < 75000/mm3 
 
<50000/mm3  
No bleeding       
Significant 
bleeding risk 
5000-30000 <100000/mm3    
Pre-operative </= 
50000/mm3 
   <50000/mm3 
Invasive 
procedures 
</= 
50000/mm3 
   <50000/mm3 
DIC      
Trauma  <100000/mm3 <100000/mm3   
Sepsis      
Traumatic 
brain injury 
 <100000/mm3 <100000/mm3   
Bone marrow 
failure 
    <10000/mm3 
without risk 
factors 
 
<20000/mm3 with 
risk factors (fever, 
antibiotics, 
systemic 
hemostatis 
failure) 
Not indicated    >100000/mm3 Immune-
mediated platelet 
destruction, 
thrombotic, 
thrombotic 
thrombocytopenic 
purpura, 
hemolytic uremic 
syndrome, drug-
induced or cardiac 
bypass 
thrombocytopenia 
without 
hemorrhage 
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Appendix Table 4: Summary of Guideline Recommendations and Indications for 
Clinical Use of Cryoprecipitate 
 British Columbia ASA New Zealand Cochrane 
Methodology AHCPR ASA NHMRC SHULZ 
Trigger Fibrinogen < 1.0 g/L Fibrinogen <0.8g/L -  
Inherited/acquired 
deficiency 
< 1.0 g/L    
Dysfibrinogenemia < 1.0 g/L    
DIC < 1.0 g/L  When considered 
clinically appropriate 
 
Sepsis     
Invasive procedure   When considered 
clinically appropriate 
 
Trauma  Fibrinogen <0.8-
1.0g/L 
When considered 
clinically appropriate 
 
Intracranial hemorrhage - 
During or after 
administration of tPA 
   
Hemophilia - 
Used if unresponsive 
to desmopressin 
   
Von Willebrand’s disease - 
Used if FVIII:C 
concentrates not 
available 
   
Factor XIII or fibronectin 
deficiency 
- 
Used if FVIII:C 
concentrates not 
available 
   
Not indicated Fibrin glue. sepsis Fibrinogen >1.5g/L Hemophilia, von 
Willebrand’s disease, 
deficiencies of XIII or 
fibronectin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P a g e  | 61 
 
 
 
Appendix Table 5. Organizations that have endorsed or that are using GRADE 
Organizations 
World Health Organization – International 
Endocrine Society – USA 
American College of Chest Physicians – USA 
UpToDate – Putting Clinical Information Into Practice - USA 
Agenzia sanitaria regionale, Bologna – Italia 
Ministry of Health and Long-term Care, Ontario – Canada 
Surviving Sepsis – International 
Arztliches Zentrum fur Qualitat in der Medizin – Germany 
American Thoracic Society – USA 
American College of Physicians – USA 
The Cochrane Collaboration – International 
Kidney Disease: Improving Global Outcome – International 
European Society of Thoracic Surgeons – International 
British Medical Journal – UK 
Journal of Infection in Developing Countries – International 
Agency for Healthcare Research and Quality (AHRQ) – USA 
Society of Critical Care Medicine (SCCM) – USA 
National Institute for Clinical Excellence (NICE) – UK 
Norwegian Knowledge Centre for the Health Services – Norway 
The University of Pennsylvania Health System Center for Evidence-based Practice – USA 
German Center for Evidence-based Nursing “sapere aude” – Germany 
Evidence-based Nursing Sudirol, Alto Adige – Italy 
Society for Vascular Surgery – USA 
BMJ Clinical Evidence – UK 
EBM Guidelines – Finland/International 
Polish Institute for EBM – Poland 
European Respiratory Society (ERS) – Europe 
Japanese Society for Temporomandibular Joint – Japan 
National Board of Health and Welfare – Sweden 
COMPUS at The Canadian Agency for Drugs and Technologies in Health (CADTH) – Canada 
Infectious Diseases Society of America – USA 
Spanish Society for Family and Community Medicine – Spain 
Emergency Medical Services for Children National Resource Center – USA 
SBU – The Swedish Council on Technology Assessment in Health Care – Sweden 
The Scottish Intercollegiate Guidelines Network (SIGN) – UK 
Evidence-Based Tuberculosis Diagnosis (tbevidence.org) – Canada 
National & Gulf Center for Evidence Based Health Practice (NGCEBHP) – Saudi Arabia 
American Society for Gastrointestinal Endoscopy – USA 
European Association for the Study of the Liver – Europe 
CDC’s Healthcare Infection Control Practices Advisory Committee (HICPAC) – USA 
Finnish Office for Health Technology Assessment – Finland 
NHS Quality Improvement Scotland – UK 
The American Association for the Study of Liver Diseases – USA 
The Canadian Cardiovascular Society – Canada 
The World Allergy Organization (WAO) – International 
Kaiser Permanente – USA 
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) – Europe 
World Interactive Network Focused on Critical Ultrasound – International 
Critical Ultrasound Journal – Italy 
American Society for Colposcopy and Cervical Pathology – USA 
The Dutch Institute for Healthcare Improvement CBO – The Netherlands 
Kleijnen Systematic Reviews Ltd – UK 
American Gastroenterological Association – USA 
Ludwig Boltzmann Institut – Austria 
Canadian Task Force on Preventative Health Care – Canada 
Canadian Society of Nephrology – Canada 
The National Kidney Foundation / KDOQI – USA 
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